Onkos Surgical® continues its innovation in musculoskeletal oncology and complex orthopaedic reconstruction with the launch of the ELEOS™ Proximal Tibia with BioGrip™ technology

PARSIPPANY, New Jersey, December 21, 2020 – Onkos Surgical, Inc., an innovator in the field of
musculoskeletal oncology and personalized orthopaedics, continues to deliver on its promise of
commercializing innovative solutions with the launch of the new ELEOS Proximal Tibia with BioGrip
technology. The product, used in complex tumor and orthopaedic reconstructive procedures, is the
first FDA cleared, 3D printed limb salvage replacement. BioGrip and its novel 3D printed porous
structure, will be leveraged on future innovation across the ELEOS Limb Salvage family of products
and other personalized implant solutions, capitalizing on Onkos’ experience and expertise in the use
of advanced additive manufacturing techniques.

Steven Gitelis, MD, Onkos Surgical Chief Medical Officer, Rush Medical College Endowed Professor
and Chief of the Musculoskeletal Oncology Program at Rush Cancer Center said, “The new ELEOS
Proximal Tibia with BioGrip offers features that are intended to help address the challenges
associated with proximal tibial replacement. Careful consideration went into the design and trajectory
of the suture holes which are designed to provide fixation for important soft tissue anatomy. The
BioGrip 3D printed design provides a consistent porous structure on the implant in key anatomical
areas to support bone and soft tissue apposition. These elements deliver meaningful enhancements
in a procedure that presents many clinical challenges.”

Patrick Treacy, co-founder and CEO stated, “2020 was an incredibly gratifying year for Onkos
Surgical. We launched four new products – our New ELEOS Proximal Femoral Replacement, ELEOS
Proximal Tibia with BioGrip, GenVie™ Magnesium Bone Scaffold, and uDesign™ on Demand
personalized surgical planning – all of which have brought innovation and focused improvements to
surgeons and patients. Our new US partnership with Integrum AB to distribute the OPRA™
osseointegration device has meant improved quality of life for amputee patients. We continue to
invest heavily in our R&D engine to ensure we maintain a consistent drumbeat of new product
introductions that will provide meaningful advancements for our surgeons and the patients they care

Sean Curry, Senior Vice President of Commercial Operations, added, “When we started Onkos
Surgical, we said we would emphasize key innovation verticals that help surgeons address the
clinical challenges related to soft tissue attachment, aseptic loosening and infection management.
We remain uniquely positioned and focused on delivering on that promise. 2020 presented us with
as an opportunity to accelerate our innovation and continue to disrupt the status quo for the benefit of
many surgeons and patients.”

Cautions Concerning Forward-Looking Statements

Certain statements made in this release that are not statements of historical or current facts are
forward-looking statements which involve known and unknown risks, uncertainties and other factors
that may cause the actual results, performance, or achievements of the company to be materially
different from historical results or from any future results or projections expressed or implied by such
forward-looking statements. In many cases, forward-looking statements can be identified by terms
such as “future,” “believes,” “expects,” “may,” “will,” “should,” “potential,” “estimates,” “intends,”
“anticipates” or “plans” or the negative of these terms or other comparable terminology. Forwardlooking
statements are based upon management’s beliefs, assumptions and current expectations but
are subject to known and unknown risks and uncertainties including, without limitation, delays
potentially caused by the need for institutional review board approval and product training, distribution
challenges, unexpected product efficacy and safety concerns, product or raw material availability and
other supply constraints. Although management believes that the expectations reflected in the
forward-looking statements are reasonable, forward-looking statements are not, and should not be
relied upon as a guarantee of future performance or results. The forward-looking statements included
are made only as the date of this release. The company assumes no obligation to update any
information or forward-looking statements contained herein, save for any information required to be
disclosed by law.

About Onkos Surgical

Based in Parsippany, N.J., Onkos Surgical is a privately held surgical oncology company founded in
2015. We believe that individuals with cancer requiring surgery deserve solutions designed
specifically for them. This principle is the driving force behind our Precision Orthopaedic Oncology
initiatives. Built on a digital platform, our solutions are rooted in unmatched expertise in patient
imaging analysis, personalized surgical planning, and the latest advancements in 3D printing. At
Onkos, we are passionate about reducing complexity for our customers and addressing the clinical
challenges associated with tumor surgery. www.onkossurgical.com